Merck & Co., Inc.
MRKNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 7, 2026Score 9/30242% above fair value
$149.52+3.19 (+2.18%)
Close on Oct 30, 2026Market cap $368.89BP/E 119.6Yield 2.19%
Merck Zerbaxa (ceftolozane and tazobactam) by Year
Zerbaxa (ceftolozane and tazobactam) — Worldwide reported growth YoY (%) (%)
Merck Zerbaxa (ceftolozane and tazobactam): 24.0% in FY2025, up 8.0 pts from a year earlier.
Latest, FY2025
24.0%
Period ended Dec 31, 2025
Change on a year earlier
+8.0 pts
16.0% in FY2024
History
5 years
Since FY2020
Sources
5
Documents cited below
Where the FY2025 figure comes from
“|| Zerbaxa | 312 | 252 | 24 | 186 | 146 | 28 | 126 | 106 | 18”
Source: Form 8-K (tm264564d1_ex99-1.htm, filed 2026-02-03) ↗
Reported in Form 8-K Table 3 / 3a / 3b Product Sales.
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Zerbaxa (ceftolozane and tazobactam) — Worldwide reported growth YoY (%) (%) | Year on year | Source |
|---|---|---|---|---|
| FY2025 | Dec 31, 2025 | 24.0% | +8.0 pts | Form 8-K (tm264564d1_ex99-1.htm, filed 2026-02-03) ↗ |
| FY2024 | Dec 31, 2024 | 16.0% | -13.0 pts | Form 8-K (tm255059d1_ex99-1.htm, filed 2025-02-04) ↗ |
| FY2023 | Dec 31, 2023 | 29.0% | – | Form 8-K (tm244517d1_ex99-1.htm, filed 2024-02-01) ↗ |
| FY2021 | Dec 31, 2021 | -101.0% | -109.0 pts | Form 8-K (tm222755d1_ex99-1.htm, filed 2022-02-03) ↗ |
| FY2020 | Dec 31, 2020 | 8.0% | – | Form 8-K (tm213179d2_ex99-1.htm, filed 2021-02-04) ↗ |
Cite this data
StockData. (2026). Merck Zerbaxa (ceftolozane and tazobactam) (%), annual FY2020–FY2025 [Data set]. Compiled from Merck SEC filings and investor materials. https://stockdatahq.com/stocks/mrk/kpis/rev-zerbaxa-ww-nom-yoy
See every metric in the Merck KPI table. Data updated Oct 26, 2026.